Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non–Small-Cell Lung Cancer: A California Cancer Consortium Trial

BACKGROUND: The proteasome inhibitor bortezomib sensitizes tumor cells to chemotherapy-induced apoptosis. In preclinical non–small-cell lung cancer (NSCLC) models, p53-dependent growth arrest after bortezomib treatment resulted in reduced cytotoxicity if bortezomib preceded docetaxel. The reverse se...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lara, Primo N., Longmate, Jeff, Reckamp, Karen, Gitlitz, Barbara, Argiris, Athanassios, Ramalingam, Suresh, Belani, Chandra P., Mack, Philip C., Lau, Derick H. M., Koczywas, Mariana, Wright, John J., Shepherd, Frances A., Leighl, Natasha, Gandara, David R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3777729/
https://ncbi.nlm.nih.gov/pubmed/21273177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CLC.2011.n.004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados